IRVING, Texas and NEW YORK, Aug. 16, 2023 /PRNewswire/ -- McKesson (NYSE: MCK), a diversified healthcare services leader, and Genpact (NYSE: G), a global professional services firm focused on delivering outcomes that transform businesses, today announced that they have extended their relationship to bring continued efficiency and automation capabilities to McKesson's finance operations, utilizing automation and AI solutions.
The extension builds on a 13-year association of simplifying and standardizing McKesson's finance processes, leveraging its vision, operational excellence, and enterprise strategy roadmap, combined with Genpact's process expertise. The companies have delivered digitally-enabled automation and other advanced technologies to drive greater effectiveness and efficiencies in McKesson's finance processes.
With this extension, the partnership will focus on advancing the operating model, scaling operating capabilities with digital initiatives, and evolving customer-centric models.
"Genpact is a trusted partner in helping McKesson accelerate its digital finance vision and finance operating model to drive strategic business value," said Britt Vitalone, executive vice president and chief financial officer, McKesson. "This partnership, in combination with other finance operating initiatives, will further accelerate our multi-year strategic growth initiative, contributing solid reduction in cost of finance operations and better position McKesson to meet the needs of the healthcare industry."
Genpact has partnered with McKesson to deliver transformation to improve the delivery of finance capabilities in a more cost-efficient manner, improving customer and partner experience and Net Promoter Score (NPS).
"Rapid changes and disruption have underscored ongoing cost pressures, data management challenges, and need for agility that the healthcare industry has always faced, making it critical that leaders like McKesson continue to adapt their operating models," said Tiger Tyagarajan, president and chief executive officer, Genpact. "We look forward to continuing to innovate with McKesson to transform their finance operations globally to drive quick, strategic decisions and continue to deliver business value in a fast-paced environment."
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
About Genpact
Genpact (NYSE: G) is a global professional services firm delivering the outcomes that transform our clients' businesses and shape their future. We're guided by our real-world experience redesigning and running thousands of processes for hundreds of global companies. Our clients – including many in the Global Fortune 500 – partner with us for our unique ability to combine deep industry and functional expertise, leading talent, and proven methodologies to drive collaborative innovation that turns insights into action and delivers outcomes at scale. We create lasting competitive advantages for our clients and their customers, running digitally enabled operations and applying our Data-Tech-AI services to design, build, and transform their businesses. And we do it all with purpose. From New York to New Delhi and more than 30 countries in between, our 115,000+ team is passionate in its relentless pursuit of a world that works better for people. Get to know us at Genpact.com and on LinkedIn, Twitter, YouTube, and Facebook.
MEDIA CONTACTS:
Siya Belliappa
Genpact Media Relations
+1 7185619843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Rachel Rodriguez
McKesson Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
David Matthews
McKesson Media Relations
214.952.0833
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$579.74 |
Daily Change: | 0.52 0.09 |
Daily Volume: | 1,686,778 |
Market Cap: | US$73.590B |
November 06, 2024 August 26, 2024 August 07, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB